Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7-targeted CAR-T Cells for MRD+ T-ALL/LBL Post-Transplant
NCT07280494Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), sponsored by Peking University People's Hospital. Primary endpoint: Measurable Residual Disease Negative Rate at 1 Month. Started Aug 2025; status: recruiting.
02
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07280494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280494.